Advertisement

Hysteroscopy pp 323-333 | Cite as

Managing Essure: Difficult Insertion and Removal

Chapter

Abstract

Essure® (Bayer AG, Leverkusen, Germany) is a minimally invasive form of irreversible contraception designed for women. In 2002, this method was the first hysteroscopic sterilization method to be approved for use by the United States Food and Drug Association (FDA) [1–3]. The transcervical route offered an attractive alternative to the widely used transabdominal approach of sterilization. Moreover, it does not require abdominal wall incisions or general anaesthesia and can be performed on out-patient basis [4, 5]. Since its introduction on the market, more than 750,000 devices were sold [6, 7].

References

  1. 1.
    Adelman MR, Dassel MW, Sharp HT. Management of complications encountered with Essure hysteroscopic sterilization: a systematic review. J Minim Invasive Gynecol. 2014;21(5):733–43.CrossRefPubMedGoogle Scholar
  2. 2.
    Andersson S, Eriksson S, Mints M. Hysteroscopic female sterilization with Essure in an outpatient setting. Acta Obstet Gynecol Scand. 2009;88(6):743–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Chudnoff SG, Nichols JE Jr, Levie M. Hysteroscopic Essure inserts for permanent contraception: extended follow-up results of a phase III multicenter international study. J Minim Invasive Gynecol. 2015;22(6):951–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Cooper J. Microinsert nonincisional hysteroscopic sterilization. Obstet Gynecol. 2003;102(1):59–67.PubMedGoogle Scholar
  5. 5.
    Kerin JF, Cooper JM, Price T, Van Herendael BJ, Cayuela-Font E, Cher D, et al. Hysteroscopic sterilization using a micro-insert device: results of a multicentre Phase II study. Hum Reprod. 2003;18(6):1223–30.CrossRefPubMedGoogle Scholar
  6. 6.
    http://essuremd.com/home: Bayer. Vvisited 18 Aug 2016.
  7. 7.
    Dhruva SS, Ross JS, Gariepy AM. Revisiting Essure—toward safe and effective sterilization. N Engl J Med. 2015;373(15):e17.CrossRefPubMedGoogle Scholar
  8. 8.
    Greenberg JA. Hysteroscopic sterilization: history and current methods. Rev Obstet Gynecol. 2008;1(3):113.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Al-Safi Z, Shavell VI, Katz LE, Berman JM. Nickel hypersensitivity associated with an intratubal microinsert system. Obstet Gynecol. 2011;117(2 Pt 2):461–2.CrossRefPubMedGoogle Scholar
  10. 10.
    Hitzerd E, Schreuder HW, Vleugels MP, Veersema S. Twelve-year retrospective review of unintended pregnancies after Essure sterilization in the Netherlands. Fertil Steril. 2016;105(4):932–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Valle RF, Carignan CS, Wright TC. Tissue response to the STOP microcoil transcervical permanent contraceptive device: results from a prehysterectomy study. Fertil Steril. 2001;76(5):974–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Greenberg JA. Essure® ESS305. Rev Obstet Gynecol. 2008;1(1):39–40.PubMedCentralGoogle Scholar
  13. 13.
    Essure problems Facebook group. Available from: https://www.facebook.com/groups/Essureproblems/. Visited 18 Aug 2016.
  14. 14.
    Bahk CY, Goshgarian M, Donahue K, Freifeld CC, Menone CM, Pierce CE, et al. Increasing patient engagement in pharmacovigilance through online community outreach and mobile reporting applications: an analysis of adverse event reporting for the Essure device in the US. Pharm Med. 2015;29(6):331–40.CrossRefGoogle Scholar
  15. 15.
    Federal Register. Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee: notice of meeting. http://www.federalregister.gov/articles/2015/07/22/2015-17985/obstetrics-and-gynecology-devices-panel-of-the-medical-devices-advisory-committee-notice-of-meeting. 22 July 2015.
  16. 16.
    Bibas N, Lassere J, Paul C, Aquilina C, Giordano-Labadie F. Nickel-induced systemic contact dermatitis and intratubal implants: the baboon syndrome revisited. Dermatitis. 2013;24(1):35–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Yunker AC, Ritch JM, Robinson EF, Golish CT. Incidence and risk factors for chronic pelvic pain after hysteroscopic sterilization. J Minim Invasive Gynecol. 2015;22(3):390–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Casey J, Aguirre F, Yunker A. Outcomes of laparoscopic removal of the Essure sterilization device for pelvic pain: a case series. Contraception. 2016;94(2):190–2.CrossRefPubMedGoogle Scholar
  19. 19.
    Hostynek JJ. Sensitization to nickel: etiology, epidemiology, immune reactions, prevention, and therapy. Rev Environ Health. 2006;21(4):253–80.CrossRefPubMedGoogle Scholar
  20. 20.
    Zurawin RK, Zurawin JL. Adverse events due to suspected nickel hypersensitivity in patients with Essure micro-inserts. J Minim Invasive Gynecol. 2011;18(4):475–82.CrossRefPubMedGoogle Scholar
  21. 21.
    van der Zee K, Sanderman R. Psychometric qualities of the RAND 36-item Health Survey 1.0: a multidimensional measure of general health status. Int J Behav Med. 1996;3:104–22.CrossRefGoogle Scholar
  22. 22.
    Van der Zee K, Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND-36, een handleiding. Tweede herziene druk UMCG/Rijksuniversiteit Groningen, Research Institute SHARE; 2012.Google Scholar
  23. 23.
    Legendre G, Levaillant J-M, Faivre E, Deffieux X, Gervaise A, Fernandez H. 3D ultrasound to assess the position of tubal sterilization microinserts. Hum Reprod. 2011;26(10):2683–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Bettocchi S. New area of office hysteroscopy. Am Assoc Gynecol Laparosc. 1996;3:S4.CrossRefGoogle Scholar
  25. 25.
    Sinha D, Kalathy V, Gupta J, Clark T. The feasibility, success and patient satisfaction associated with outpatient hysteroscopic sterilisation. BJOG. 2007;114(6):676–83.CrossRefPubMedGoogle Scholar
  26. 26.
    Chern B, Siow A. Initial Asian experience in hysteroscopic sterilisation using the Essure permanent birth control device. BJOG. 2005;112(9):1322–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Moawad N, Mansuria S. Essure perforation and chronic pelvic pain. J Minim Invasive Gynecol. 2011;18(3):285–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Al-Safi ZA, Shavell VI, Hobson DT, Berman JM, Diamond MP. Analysis of adverse events with Essure hysteroscopic sterilization reported to the Manufacturer and User Facility Device Experience database. J Minim Invasive Gynecol. 2013;20(6):825–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Lannon BM, Lee SY. Techniques for removal of the Essure hysteroscopic tubal occlusion device. Fertil Steril. 2007;88(2):497.e13–4.Google Scholar
  30. 30.
    Beckwith AW. Persistent pain after hysteroscopic sterilization with microinserts. Obstet Gynecol. 2008;111(2, Part 2):511–2.CrossRefPubMedGoogle Scholar
  31. 31.
    Hur HC, Mansuria SM, Chen BA, Lee TT. Laparoscopic management of hysteroscopic Essure sterilization complications: report of 3 cases. J Minim Invasive Gynecol. 2008;15(3):362–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Rietschel RL, Fowler JF, Warshaw EM, Belsito D, DeLeo VA, Maibach HI, et al. Detection of nickel sensitivity has increased in North American patch-test patients. Dermatitis. 2008;19(1):16–9.Google Scholar
  33. 33.
    Lerouge S, Guidoin R, Ashton T, Guidoin M, Legrand A, Douville Y, et al. Nitinol self-deployable endovascular prostheses: variability in corrosion resistance. Ann Chim. 2004;29(1):41–52.CrossRefGoogle Scholar
  34. 34.
    Ries MW, Kampmann C, Rupprecht HJ, Hintereder G, Hafner G, Meyer J. Nickel release after implantation of the Amplatzer occluder. Am Heart J. 2003;145(4):737–41.CrossRefPubMedGoogle Scholar
  35. 35.
    Jensen CS, Lisby S, Baadsgaard O, Byrialsen K, Menné T. Release of nickel ions from stainless steel alloys used in dental braces and their patch test reactivity in nickel-sensitive individuals. Contact Dermatitis. 2003;48(6):300–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Kamencic H, Thiel L, Karreman E, Thiel J. Does Essure cause significant de novo pain? A retrospective review of indications for second surgeries following Essure placement. J Minim Invasive Gynecol. 2016;23(7):1158–62.CrossRefPubMedGoogle Scholar
  37. 37.
    Estridge TD, Feldman DS. Quantification of vascular ingrowth into Dacron® velour. J Biomater Appl. 1991;6(2):157–69.CrossRefPubMedGoogle Scholar
  38. 38.
    Bartholin E. Experimenta crystalli islandici disdiaclastici quibus mira & infolita refractio detegitur. Translated into English by Archibald T. Acta Historica Scientiarium Naturalium et medicinalium 40: Danish National Library of Science and Medicine; 1991.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Reproductive Medicine and GynaecologyUniversity Medical Centre UtrechtUtrechtThe Netherlands

Personalised recommendations